Drugs / Pegylated Interferon (peg-IFN)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT01273948 Comparator | Jan 2011 → Jan 2012 | hepatitis C virus infection | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00880763 Background | Apr 2009 → Jun 2010 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated interferon (PEG-IFN) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01273948 ↗ |
| Known as | peg-IFN alfa-2a | “Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks” NCT00880763 ↗ |
| Route | Subcutaneous | “peg-IFN alfa-2a subcutaneous injection” NCT00880763 ↗ |